Salivary gland carcinomas: Molecular abnormalities as potential therapeutic targets

Current Opinion in Oncology

Volumn 20, Issue 3, 2008, Pages 270-274

  Prenen, Hans ^a   Kimpe, Marlies ^a   Nuyts, Sandra ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Molecular targets; Salivary gland carcinoma; Treatment

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIANDROGEN; ANTIBODY; AXITINIB; BORTEZOMIB; CETUXIMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAPATINIB; MEMBRANE PROTEIN; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; VASCULOTROPIN;

ADD ON THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER PATIENT; CANCER THERAPY; CARCINOGENESIS; CLINICAL TRIAL; DEMETHYLATION; DRUG APPROVAL; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG TARGETING; GENE MUTATION; HORMONAL THERAPY; HUMAN; MOLECULAR BIOLOGY; MONOTHERAPY; MULTIPLE MYELOMA; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW; SALIVARY GLAND CARCINOMA; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HUMANS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRAZINES; PYRIMIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SALIVARY GLAND NEOPLASMS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 41949123008     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282f4cf5f     Document Type: Review

References (35)

1. Pacheco-Ojeda L, Domeisen H, Narvaez M, et al. Malignant salivary gland tumors in Quito, Ecuador. ORL J Otorhinolaryngol Relat Spec 2000; 62:296-302.
2. Muscat JE, Wynder EL. A case/control study of risk factors for major salivary gland cancer. Otolaryngol Head Neck Surg 1998; 118:195-198.
3. Whatley WS, Thompson JW, Rao B. Salivary gland tumors in survivors of childhood cancer. Otolaryngol Head Neck Surg 2006; 134:385-388.
4. Hsu YC, Lu HF, Huang CC, et al. Malignant lymphoepithelial lesions of the salivary gland. Otolaryngol Head Neck Surg 2006; 134:661-666.
5. Barnes L, Everson JW, Reichart P, et al. World Health Organization classification of tumours: Pathology and genetics of head and neck tumours. Lyon, France: IARC Press; 2005.
6. Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 1986; 8:177-184.
7. Dodd RL, Slevin NJ. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. Oral Oncol 1006; 42:759-769.
8. Besmer P, Murphy JE, George PC, et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 1986; 320:415-421.
9. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577-580.
10. Jeng YM, Lin CY, Hsu HC. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett 2000; 154:107-111.
11. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031-1037.
12. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358:1421-1423.
13. Hotte SJ, Winquist EW, Lamont E, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 2005; 23:585-590.
14. Pfeffer MR, Talmi Y, Catane R, et al. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol 2007; 43:33-36. This clinical trial proves that the presence of the KIT receptor is not sufficient for clinical benefit of imatinib.
15. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with nonsmall cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158.
16. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353:2012-2024.
17. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
18. Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 2006; 24:2673-2678.
19. Glisson BS, Blumenschein G, Francisco M, et al. Phase II trial of gefitinib in patients with incurable salivary gland cancer. J Clin Oncol 2005; 23:5532.
20. Licitra LF, Locati LD, Potepan P, et al. Cetuximab (C225) in recurrent and/or metastastic salivary gland carcinomas (RMSGCs): a monoinstitutional phase II study. J Clin Oncol 2006; 24:5547.
21. Seshadri R, Firgaira FA, Hosfall DJ, et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993; 11:1936-1942.
22. Glisson B, Colevas AD, Haddad R, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 2004; 10:944-946.
23. Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 2003; 39:724-727.
24. Agulnik M, Cohen EW, Cohen RB, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and nonadenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 2007; 25:3978-3984. Although no objective responses were observed in this study with lapatinib, some patients that were previously progressing, achieved a stable disease beyond 6 months.
25. Argiris A, Goldwasser MA, Burtness B, et al. A phase II trial of PS-341 (bortezomib) followed by the addition of doxorubicin at progression in incurable adenoid cystic carcinoma of the head and neck: an Eastern Cooperative Oncology Group study. J Clin Oncol 2006; 24:5573.
26. Lim JJ, Kang S, Lee MR, et al. Expression of vascular endothelial growth factor in salivary gland carcinomas and its relation to p53, Ki-67 and prognosis. J Oral Pathol Med 2003; 32:552-561.
27. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005; 23:5474-5483.
28. Fan CY, Melhem MF, Hosal AS, et al. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg 2001; 127:1075-1079.
29. Shadaba A, Gaze MN, Grant HR. The response of adenoid cystic carcinoma to tamoxifen. J Laryngol Otol 1997; 111:1186-1189.
30. Locati LD, Quattrone P, Bossi P, et al. A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Ann Oncol 2003; 14:1327-1328.
31. van der Hulst RW, van Krieken JH, van der Kwast TH, et al. Partial remission of parotid gland carcinoma after goserelin. Lancet 1994; 344: 817.
32. Zhang CY, Mao L, Li L, et al. Promoter methylation as a common mechanism for inactivating E-cadherin in human salivary gland adenoid cystic carcinoma. Cancer 2007; 110:87-95. Altered DNA methylation might be responsible for the development of salivary gland tumors and therefore be an attractive target for anticancer therapy by DNA methyltransferase inhibitors.
33. Williams MD, Chakravarti N, Kies MS, et al. Implications of methylation patterns of cancer genes in salivary gland tumors. Clin Cancer Res 2006; 12:7353-7358.
34. Guo XL, Sun SZ, Wang WX, et al. Alterations of p16INK4a tumour suppressor gene in mucoepidermoid carcinoma of the salivary glands. Int J Oral Maxillofac Surg 2007; 36:350-353.
35. Li J, El Naggar A, Mao L. Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. Cancer 2005; 104:771-776.